Tuberculosis not only claims a lot of life, it is not easy to diagnose. Its infectious nature and the recent natural calamities which have caused massive deaths have left us helpless. Besides, the pharmaceutical industries are inclined towards lifestyle diseases and so the prevention methods, availability of sophisticated diagnostic instruments and symptoms should be highly educated among the masses. Another serious issue lies with the uncontrolled use of antibiotics by patients to supress the symptoms without knowing that they have TB. The emergence of drug-resistant strains in patients requires a careful and very long period therapeutic regiment, which needs to be monitored. The availability of complete genome sequences and computer-aided analysis to discover potential anti-TB drug targets has become a new trend. 

The available in   silico   tools enable us to decipher the interactions between therapeutic targets and novel drugs, making them invaluable in the quest for new tuberculosis treatments. Targeting the mycobacterium can be done by cell wall   synthesis hindrance or inhibiting its crucial enzymes. One of the targets to utilize is resuscitation-promoting factor B (RpfB) for the computational studies, which may be taken for further translational studies.

In a recent phase 1 clinical trial experiment, A new compound, named TBAJ-876, belonging to the diarylquinoline class of antibiotics has   shown promising results.  Currently it is in the later phases of clinical trials for the efficacy and safety study.

It comes more than the reliability on allopathic medicines and its related research in science globally to combat TB. It is highly necessary to look   for novel   science at least in TB.

TB Drugs at different stages of clinical trials